Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
Recruiting
Observational Study
Gliomas Harboring IDH1 and/or IDH2 Mutations
Glioma Glioblastoma Multiforme
Glioma of Brainstem
Glioma, Diffuse Midline, H3K27M-mutant
Glioma : Oligodendroglioma or Astrocytoma
Gliomas
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with diffuse gliomas were pathologically and molecularly diagnosed.
* The clinical case data of all patients were complete.
* Patients underwent preoperative MRI examination.
Exclusion Criteria:
* The tumor is not located in the intracranial midline.
* Cases in whic…
Contacts